A large, randomized clinical trial of estrogen and progestin as part of a Women's Health Initiative study indicated that breast cancer survivors who took hormone replacement therapy (HRT) to relieve menopausal symptoms had 3 times as many recurrences of cancer as those who did not take HRT. The 1997 Swedish study followed 434 women for a median of 5 years. Researchers found that 26 women in the HRT group and only 7 in the non-HRT group experienced a recurrence of breast cancer. The study was terminated due to the high risk of cancer recurrence from even short-term use of HRT. The study was neither blinded nor placebo-controlled, and recruitment fell short of the 1300- women goal. Despite the study's limitations, JoAnne Zujewski, MD, a medical oncologist specializing in breast cancer at the National Institutes of Health Clinical Center in Bethesda, Md, said, "As a practical matter, given what we already know about the serious risks and extremely limited benefits of HRT, these findings can be considered definitive."
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs